

PATENT  
ATTORNEY DOCKET: 58777.000012

1 FW  
Box  
SCG

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
Fumiyuki HATTORI et al. ) Group Art Unit: To Be Assigned  
Application Number: 10/642,272 ) Examiner: To Be Assigned  
Filed: August 18, 2003 )  
For: THERAPEUTIC METHODS AND AGENTS FOR DISEASES ASSOCIATED WITH  
DECREASED EXPRESSION OF AOP-1 GENE OR AOP-1

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR  
AMINO ACID SEQUENCE DISCLOSURES**

Sir,

Responsive to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("Notice") mailed June 24, 2004, Applicants submit herewith a substitute "Sequence Listing" in computer-readable form believed to be in compliance with the requirements of 37 C.F.R. §§ 1.821-1.825. A copy of the Notice is also attached. This response is filed within the two-month period set for reply without extensions of time. Accordingly, no extensions of time are necessary in conjunction with this response.

No fees are believed due in connection with this Response. However, if it is determined otherwise, the Commissioner is hereby authorized to charge the undersigned's Deposit Account No. 50-0206.

**REMARKS**

**Sequence Listing**

In reply to the Notice, and in accordance with the provisions of 37 C.F.R. §§ 1.821-1.825, Applicants submit herewith a substitute computer readable form (CRF) of the "Sequence Listing" on a 3½ inch diskette, in ASCII format as required by 37 C.F.R. § 1.821(e). Applicants also submit herewith a paper copy of the substitute "Sequence Listing", totaling fifteen (15) pages.

Support for the substitute sequence listing can be found throughout the specification and sequence listing as originally filed. In particular, support for the substitute sequence listing can be found, for example, at paragraphs [0095], [00121], [00123], [00125], [00140], [00146]. Accordingly, Applicants submit that no new matter is introduced into the specification by way of incorporation of the instant substitute sequence listing.

The undersigned hereby states that the content of the computer readable form of the substitute "Sequence Listing" and the paper copy of the substitute "Sequence Listing" submitted herewith are identical.

**Conclusion**


An indication of allowance of all claims is earnestly solicited. Early notification of a favorable consideration is respectfully requested.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Date: August 24, 2005

By:

  
\_\_\_\_\_  
Robert M. Schulman  
Registration No. 31,196

Alexander H. Spiegler  
Registration No. 56,625

HUNTON & WILLIAMS LLP  
1900 K Street, N.W.  
Suite 1200  
Washington, D.C. 20006-1109  
(202) 955-1500 (telephone)  
(202) 778-2201 (facsimile)  
RMS/JLP/AHS:sac